Reinvigorating European R&D innovation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Reinvigorating European R&D innovation

Pharmaceutical Technology Europe
Volume 22, Issue 3


The European pharmaceutical industry has long expressed its concern that the R&D environment in which it operates is less than ideal; however, the factors hampering innovation cannot be solely attributed to government policies, such as cost-containment initiatives. If European companies want to justify the high prices of their drugs and have a valid argument to counter cost-containment policies, they will need to make major medical advances — a continuing output of 'me-too' products and line extensions will do nothing to help the industry's case.

With the launch of the IMI, it looks as if many of the factors holding back innovation will finally be addressed. Those behind the initiative have emphasised the project's urgency, particularly as the US already has its own initiatives to promote innovation, such as the US Biomarker Consortium and initiatives under the FDA's Critical Path. What stakeholders will be looking for is a deadline for the IMI to deliver upon its promises. However, it will be up to the companies themselves to make the most of its outputs.

The author says...
  • The European pharma industry has lost ground to foreign rivals — R&D investment in Europe is now only approximately 70% that of the US.
  • To reinvigorate R&D, the Innovative Medicines Initiative (IMI) has been established to find clear, practical paths to accelerating drug development and stimulating regional R&D.
  • The IMI will help to foster collaborations across the region, which should reduce the development risks for all those involved.
  • The IMI's Strategic Research Agenda is organised around four areas: predictability of safety evaluation, predictability of efficacy evaluation, knowledge management, and education and training.


1. EFPIA, "The pharmaceutical industry in Europe: key facts and figures" (2008).

2. Pharmaceutical-Technology, "Lilly CEO Criticises Lack of Biopharma Innovation" (2009).

3. The In Vivio Blog, "Innovation Is the Pharmaceutical Industry's Only Salvation" (2009)

4. Private Sector Roles in Global Public Health, "Shaping incentives for private sector biotech innovation in China" (2009).

5. RNCOS, Indian Pharma to Get Rs 2,500 Crore Investment (2009).

6. IMI, The Innovative Medicines Initiative: Scientific Priorities/Research Agenda (2009).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here